Media headlines about OvaScience (NASDAQ:OVAS) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. OvaScience earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.7909014370571 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- OvaScience, Inc. (OVAS) is at $1.38 per share and AdCare Health Systems, Inc. (ADK) is listed at $0.91 – Stocks Gallery (stocksgallery.com)
- Healthcare Stock recommendation to Hold: OvaScience, Inc. (OVAS) – Street Observer (press release) (streetobserver.com)
- IVF Devices and Consumables Market Expected to Reach $4,972 Million, Globally by 2023 (sbwire.com)
- ETFs with exposure to OvaScience, Inc. : October 5, 2017 (finance.yahoo.com)
- ETFs with exposure to OvaScience, Inc. : September 25, 2017 (finance.yahoo.com)
Several equities research analysts recently weighed in on OVAS shares. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Wednesday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of OvaScience in a research note on Thursday, June 22nd.
Shares of OvaScience (NASDAQ OVAS) traded up 1.08% during midday trading on Friday, hitting $1.40. 81,077 shares of the company’s stock traded hands. The company has a 50 day moving average price of $1.40 and a 200 day moving average price of $1.48. OvaScience has a 1-year low of $1.25 and a 1-year high of $7.54. The firm’s market capitalization is $49.96 million.
OvaScience (NASDAQ:OVAS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The company’s revenue for the quarter was down 55.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.62) earnings per share. Equities analysts anticipate that OvaScience will post ($1.66) earnings per share for the current year.
WARNING: This news story was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://transcriptdaily.com/2017/10/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-ovascience-ovas-stock-price.html.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.